technology

Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk

6 Haziran 2026Science Daily

A large study found that women taking GLP-1 drugs, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were about 30% less likely to develop breast cancer. Researchers say the findings are promising but not yet proof, and clinical trials are now being planned to test whether these drugs could help p…
Published 6 minutes ago, this story falls under technology coverage. Follow updates from Science Daily for related developments.
This story was reported by Science Daily. Key takeaways: • A large study found that women taking GLP-1 drugs, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were about 30% less likely to develop breast cancer.

NewsAI özeti

ℹ️ This article was automatically processed by NewsAI. A standard summary is shown while the AI service is temporarily unavailable.

Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.

Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.